Clinical Trial Finder
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Study Purpose
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
Recruitment Criteria
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Inclusion Criteria:
- - Have measurable disease per RECIST v 1.1.
as assessed by local site investigator/radiology.Exclusion Criteria:
- - Has received prior radiotherapy within 2 weeks of start of study treatment or have had
a history of radiation pneumonitis.
- Has had an allogeneic tissue/solid organ transplantTrial Details
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
Arms
Experimental: Dose escalation of Q702 in combination with fixed dose of pembrolizumab
Give one week on/one week off at selected dose level
Experimental: Dose expansion of Q702 in combination with fixed dose of pembrolizumab
Give intravenously once every three week at 200 mg
Interventions
Drug: - Q702
The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
Biological: - Pembrolizumab
Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Recruiting
Address
University of Southern California
Los Angeles, California, 90033
Site Contact
See Central Contact
[email protected]
+82-31-8060-1610
Status
Recruiting
Address
Norton Cancer Institute
Louisville, Kentucky, 40202
Site Contact
[email protected]
+82-31-8060-1610
International Sites
Status
Recruiting
Address
CHA Bundang Medical Center
Seongnam-si, ,
Site Contact
See Central Contact
[email protected]
+82-31-8060-1610
Status
Not yet recruiting
Address
Asan Medical Center
Seoul, ,
Site Contact
See Central Contact
[email protected]
+82-31-8060-1610
Status
Recruiting
Address
Samsung Medical Center
Seoul, ,
Site Contact
See Central Contact
[email protected]
+82-31-8060-1610
Status
Recruiting
Address
Seoul National University Hospital
Seoul, ,
Site Contact
See Central Contact
[email protected]
+82-31-8060-1610
Status
Recruiting
Address
Severance Hospital
Seoul, ,
Site Contact
See Central Contact
[email protected]
+82-31-8060-1610
Privacy Overview